Clinical Trial Update: Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating anti-CD19 CAR T cells in pediatric patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: Bambino Gesù Hospital and Research Institute | Conditions: CD19-ALL, CD19-LNH | Phase 1, Phase 2 | Status: COMPLETED